1 / 60

Influenza Update

Influenza Update. Eliane Haron, M.D. Influenza Viruses. Orthomyxoviruses Enveloped, RNA viruses Estimated to measure 80-120 nm in diameter Subtypes A, B and C Mainly A and B cause significant infection in humans. Subtype C can cause mild infection without seasonality.

vwillingham
Download Presentation

Influenza Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Influenza Update Eliane Haron, M.D.

  2. Influenza Viruses • Orthomyxoviruses • Enveloped, RNA viruses • Estimated to measure 80-120 nm in diameter • Subtypes A, B and C • Mainly A and B cause significant infection in humans. • Subtype C can cause mild infection without seasonality

  3. Influenza – Surface Glycoproteins • Hemaglutinin • Sialic acid receptor-binding molecule, which binds to sialic acid residues present on the surface of respiratory epithelial cells. • Mediates entry of the virus into the target cell • 16 types H1-H16 • Mainly H1, H2, H3 cause disease in humans

  4. Influenza- Surface Glycoproteins • Neuraminidase • Responsible for cleavage of the newly-formed virions from the host cell. • Inhibition of this protein halts viral replication. • 9 types N1-N9 • Mostly N1 and N2 are involved in human infections

  5. Current circulating virus • Since 1977, AH1N1 and A/H3N2 have circulated along with influenza B viruses • In 2001-2002 a novel reassortment strain A/H1N2 appeared but did not cause extensive outbreaks • In 2004-2005, influenza A isolates were mostly A/H3N2

  6. Influenza - Transmission • Usually transmitted by direct contact and inhalation of large infectious droplets produced during coughing and sneezing • Hands and other objects can get contaminated with infected respiratory secretions, and subsequent contact with mucosal surfaces can transmit the virus • Close contact needed (<3 feet) • Droplet precautions in hospitalized patients • For 5 days in normal hosts • For the duration of illness in immunocompromised patients

  7. Clinical Manifestations • Uncomplicated Influenza • Abrupt onset of fever, HA, myalgias, malaise along with respiratory symptoms particularly cough and sore throat. • Illness usually improves/resolves in 3-7 days • Occasional post infectious asthenia

  8. Clinical Manifestations • Complications • Primary Influenza Pneumonia • Secondary Bacterial Pneumonia • Strep. pneumoniae; Staph aureus • Exacerbation of fever and respiratory symptoms after initial improvement of influenza symptoms • Other complications • Myositis, • CNS involvement: encephalitis, transverse myelitis, aseptic meningitis, Guillan-Barre’ syndrome. • Myocarditis and pericarditis (rare).

  9. Influenza- Diagnosis • Clinical Diagnosis • Clinical diagnosis is straightforward during a flu epidemic • In sporadic cases, symptoms can be indistinguishable from other acute respiratory infections • Laboratory Diagnosis • Viral cultures of respiratory secretions (nasal washes, sputum, throat swab, BAL) • Rapid detection tests (EIA, IF, PCR) • Serologic tests

  10. Influenza- Treatment • Adamantanes (Amantadine/Rimantadine) • Inhibition of viral uncoating inside the host cell due to interaction with the M2 protein of susceptible viruses • Active against Influenza A, • No activity against Influenza B • Both drugs have shown a decrease in clinical symptoms and a reduction in the levels and duration of viral shedding • Need to be started within 48 hours of symptoms • Resistant isolates can develop

  11. Influenza- Treatment • Amantadine • Dose: • 100mg PO q12hs x 5days for rx acute infection • 100mg PO q12hs x 10 days post exposure, 2-4 wks post vaccine • Excreted unaltered in urine • Needs dose correction in renal insufficiency • CNS side effects such as insomnia, dizziness, difficulty concentrating, seizures • Main use: Treatment and prophylaxis

  12. Influenza- Treatment • Rimantadine • Dose: • 100mgPO q12hs x 7 days for rx acute infection • Less than 15% excreted unchanged in urine • Dose should be decreases by half in ESRD, hepatic insufficiency and in elderly patients • Considerably less CNS side effects than amantadine

  13. Influenza- Treatment • Neuraminidase Inhibitors: • Zanamivir and Olseltamivir • Active against Influenza A and B viruses • Must be given within 48hs of development of symptoms • Mechanism of action: mimic the natural substrate, fitting into the neuraminidase site of the virus • Halts viral replication by impeding release of new formed virions.

  14. Mechanism of Action of Neuraminidase Inhibitors Moscona, A. N Engl J Med 2005;353:1363-1373

  15. Influenza- Treatment • Zanamivir • Dose: two 5mg inhalations twice daily x 5 days • Powder for inhalation • Highly concentrated in respiratory tract when inhaled • No bio-availability • Only 5%-15% of the drug is absorbed and excreted in the urine • Side effects: mainly bronchospasm, cough

  16. Influenza- Treatment • Oseltamivir • Dose: • 75mg PO q 12hs x 5 days for Rx • 75 mg PO daily for prophylaxis • Good oral bioavailability (capsule or suspension) • Mainly excreted in the urine • Needs dose correction for renal insufficiency • Side Effects: nausea, vomiting, diarrhea

  17. Influenza - Prevention

  18. Influenza Vaccine • 2005-2006 vaccine strains • A/NewCaledonia/20/99 (H1N1) • A/California/7/2004(H3N2) • B/Shanghai/361/2002

  19. Coverage 2004-2005 Season • Children 6-23 months old: 48.4% • Adults ≥ 65 years old: 62.7% • Non-priority adults: 8.8% (2003-2004: 17.8%) Centers for Disease Control and Prevention, MMWR, 2005.

  20. Priority Groups For Influenza Vaccination, 2005-2006 • Children 6-23 months of age • Adults >50 years • Persons 2-64 years of age with underlying chronic medical conditions • Women who will be pregnant during influenza season

  21. Priority Groups For Influenza Vaccination, 2005-2006 • Residents and staff of nursing homes and long-term care facilities • Children 6 months-18 years of age on chronic aspirin therapy • Healthcare workers with direct, face-to-face patient contact • Household contacts and out-of-home caregivers of persons in a high-risk group

  22. Inactivated Influenza VaccineRecommendations • Persons with the following chronic illnesses should be considered for inactivated influenza vaccine: • pulmonary (e.g., asthma, COPD) • cardiovascular (e.g., CHF) • metabolic (e.g., diabetes) • renal dysfunction • hemoglobinopathy • immunosuppression, including HIV infection

  23. New Chronic Disease Risk Group (2005-2006) • Conditions (e.g. cognitive dysfunction, spinal cord injuries, seizure disorders or other neuromuscular disorders) that can: • Compromise respiratory function • Compromise the handling of respiratory secretions • Increase the risk of aspiration

  24. Live Attenuated Influenza Vaccine Approved by FDA June 2003

  25. Live Attenuated Influenza Vaccine (LAIV) Indications • Healthy* persons 5–49 years of age • Household contacts of persons at increased risk of complications of influenza • Health care workers *Persons who do not have medical conditions that increase their risk of complications of influenza

  26. LAIVPersons Who Should not be Vaccinated • Children <5 years of age* • Persons >50 years of age* • Persons with underlying medical conditions* • Pregnant women* • Persons immunosuppressed from disease (including HIV) or drugs* *These persons should receive inactivated influenza vaccine

  27. LAIVPersons Who Should not be Vaccinated • Children or adolescents receiving long-term therapy with aspirin or other salicylates* • Severe (anaphylactic) allergy to egg or other vaccine components • History of Guillain-Barre´ syndrome *These persons should receive inactivated influenza vaccine

  28. Avian Influenza • Caused by Influenza A viruses • Can affect domestic poultry and wild birds • Migratory birds are considered the natural reservoir of influenza viruses

  29. Avian Influenza • Two forms of infection in birds • Low Pathogenicity • Mild disease, ruffled feathers, drop in egg production • Can go undetected • High Pathogenicity • Dramatic bird disease affecting multiple organs • Spreads rapidly through poultry flocks • High mortality, usually within 48 hours

  30. Implications of Avian Influenza in Human Health • Direct Infection • Virus crosses from birds to humans, causing severe disease in humans • Birds shed large amounts of virus in their feces • Caused by direct contact with poultry or objects/surfaces contaminated with poultry feces • Exposure during slaughter, de-feathering, butchering and preparing for cooking most likely • No evidence of transmission through cooked foods

  31. Implications of Avian Influenza in Human Health • Transformation of the virus into a form that is highly infectious to humans and can spread easily from person to person • Adaptive mutation • Reassortment • Will trigger a pandemic given lack of immunity of the population

  32. The Two Mechanisms whereby Pandemic Influenza Originates Belshe, R. B. N Engl J Med 2005;353:2209-2211

  33. Avian Influenza A(H5N1) in Humans • Affects younger population; very high mortality • Incubation may be longer (up to 8 days) • Clinical presentation includes high fever, and an influenza-like illness with lower tract respiratory symptoms, pleuritic chest pain, diarrhea, vomiting, abdominal pain, bleeding from gums and nose • CXR with diffuse, patchy, multi-focal infiltrates • Progression to respiratory failure and ARDS requiring ventilatory support • Labs: leukopenia, lymphopenia, thrombocytopenia, elevated LFTs, renal function tests • Virologic diagnosis: • Viral cultures or viral RNA in pharyngeal samples (rather than nasal). • Viral loads higher than A(H1N1) or A(H3N2) viruses • Commercial rapid antigen tests less sensitive in detecting A(H5N1)

  34. Proposed Mechanism of the Cytokine Storm Evoked by Influenzavirus Osterholm, M. T. N Engl J Med 2005;352:1839-1842

  35. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO 29 November 2005

  36. Belshe, R. B. N Engl J Med 2005;353:2209-2211

More Related